Lyell Immunopharma Inc (LYEL)
1.49
-0.09
(-5.70%)
USD |
NASDAQ |
Jul 02, 16:00
1.49
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Research and Development Expense (TTM): 181.49M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 181.49M |
| December 31, 2023 | 182.94M |
| September 30, 2023 | 173.98M |
| June 30, 2023 | 171.74M |
| March 31, 2023 | 167.99M |
| December 31, 2022 | 159.19M |
| September 30, 2022 | 140.44M |
| Date | Value |
|---|---|
| June 30, 2022 | 130.27M |
| March 31, 2022 | 132.99M |
| December 31, 2021 | 138.69M |
| September 30, 2021 | 154.50M |
| June 30, 2021 | 147.57M |
| March 31, 2021 | 198.27M |
| December 31, 2020 | 182.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
130.27M
Minimum
Jun 2022
198.27M
Maximum
Mar 2021
161.59M
Average
163.59M
Median
Research and Development Expense (TTM) Benchmarks
| GlycoMimetics Inc | 20.68M |
| Candel Therapeutics Inc | 23.14M |
| Eliem Therapeutics Inc | 10.78M |
| Entrada Therapeutics Inc | 105.39M |
| NovaBay Pharmaceuticals Inc | 0.061M |